top of page
PARTNERS WITH
Venetoclax
Anti-neoplastic
MECHANISM OF ACTION
BCL-2 inhibitor
MECHANISM OF KIDNEY INJURY
CLINICAL KIDNEY SYNDROME
CARDIOVASCULAR ADVERSE EFFECTS
LYTE ABNORMALITIES
RISK FACTORS
MITIGATION STRATEGIES
SUGGESTIONS
NOTES/COMMENTS
eGFR < 60 ml/min, no dose adjustment
eGFR < 30 ml/min, alternative drug vs full dose( unclear)
PHARMACOKINETICS
Molecular Weight
Volume of Distribution
Plasma Protein Binding
>99%
Metabolism
Bioavailability
Half-life elimination
Time to peak
Excretion
Urine, 1.1%
Dialyzable?
No
REF:
PATHOLOGY SLIDES:
ENTRY UPDATES:
Raad Chowdhury
United States
Sep 25, 2022
bottom of page